{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T23:44:56Z","timestamp":1761954296796,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1053\/j.seminhematol.2008.03.011","type":"journal-article","created":{"date-parts":[[2008,6,8]],"date-time":"2008-06-08T04:13:01Z","timestamp":1212898381000},"page":"S38-S41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"S1","title":["Single-Dose Recombinant Activated Factor VII Therapy in Hemophilia Patients With Inhibitors"],"prefix":"10.1053","volume":"45","author":[{"given":"Gili","family":"Kenet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uri","family":"Martinowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2008.03.011_bib1","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1365-2141.2005.05605.x","article-title":"Environmental risk factors for inhibitor development in children with haemophilia A: A case-control study","volume":"130","author":"Santagostino","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2008.03.011_bib2","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1111\/j.1538-7836.2005.01375.x","article-title":"Cellular immune responses in hemophilia: Why do inhibitors develop in some, but not all hemophiliacs?","volume":"3","author":"White","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1053\/j.seminhematol.2008.03.011_bib3","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1055\/s-2000-9821","article-title":"Inhibitor antibodies to factor VIII and factor IX: Management","volume":"26","author":"Lusher","year":"2000","journal-title":"Semin Thromb Hemost"},{"key":"10.1053\/j.seminhematol.2008.03.011_bib4","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1055\/s-2000-8457","article-title":"Pharmacokinetics of recombinant activated factor VII (rFVIIa)","volume":"26","author":"Erhardtsen","year":"2000","journal-title":"Semin Thromb Hemost"},{"key":"10.1053\/j.seminhematol.2008.03.011_bib5","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1055\/s-0037-1615388","article-title":"Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors","volume":"80","author":"Key","year":"1998","journal-title":"Thromb Haemost"},{"issue":"suppl 1","key":"10.1053\/j.seminhematol.2008.03.011_bib6","first-page":"S107","article-title":"Home treatment with recombinant activated factor VII: Results from one centre","volume":"9","author":"Ingerslev","year":"1998","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1053\/j.seminhematol.2008.03.011_bib7","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1160\/TH03-05-0301","article-title":"Injection of recombinant activated factor VII can induce transient increase in circulating procoagulant microparticles","volume":"91","author":"Proulle","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.seminhematol.2008.03.011_bib8","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1055\/s-0037-1613465","article-title":"Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion","volume":"89","author":"Carr","year":"2003","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.seminhematol.2008.03.011_bib9","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1538-7836.2005.01127.x","article-title":"The effect of platelets on fibrin gel structure formed in the presence of recombinant factor VIIa in hemophilia plasma and in plasma from a patient with Glanzmann thrombasthenia","volume":"3","author":"He","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1053\/j.seminhematol.2008.03.011_bib10","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/00001721-199811000-00003","article-title":"The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an international normalized ratio above 2.0","volume":"9","author":"Erhardtsen","year":"1998","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1053\/j.seminhematol.2008.03.011_bib11","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/0049-3848(96)00028-X","article-title":"Variability in platelet procoagulant activity in healthy volunteers","volume":"81","author":"Sumner","year":"1996","journal-title":"Thromb Res"},{"issue":"suppl 1","key":"10.1053\/j.seminhematol.2008.03.011_bib12","first-page":"S97","article-title":"Experiences with continuous infusion of recombinant activated factor VII","volume":"9","author":"Schulman","year":"1998","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1053\/j.seminhematol.2008.03.011_bib13","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2516.2004.00925.x","article-title":"Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A","volume":"10","author":"Villar","year":"2004","journal-title":"Haemophilia"},{"issue":"suppl 1","key":"10.1053\/j.seminhematol.2008.03.011_bib14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/j.seminhematol.2003.11.002","article-title":"Dose optimization of recombinant factor VIIa for control of mild to moderate bleeds in inhibitor patients: Improved efficacy with higher dosing","volume":"41","author":"Abshire","year":"2004","journal-title":"Semin Hematol"},{"key":"10.1053\/j.seminhematol.2008.03.011_bib15","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1046\/j.1538-7836.2003.00059.x","article-title":"A new approach to treatment of bleeding episodes in young hemophilia patients: A single bolus megadose of recombinant activated factor VII (NovoSeven)","volume":"1","author":"Kenet","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1053\/j.seminhematol.2008.03.011_bib16","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1046\/j.1365-2516.2001.00553.x","article-title":"Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures","volume":"7","author":"Cooper","year":"2001","journal-title":"Haemophilia"},{"key":"10.1053\/j.seminhematol.2008.03.011_bib17","first-page":"53","article-title":"High dose recombinant activated factor VII for treatment of patients with haemophilia and inhibitors","volume":"10","author":"Kenet","year":"2004","journal-title":"Haemophilia"},{"key":"10.1053\/j.seminhematol.2008.03.011_bib18","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1365-2516.2005.01075.x","article-title":"Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: Analysis from the Hemophilia and Thrombosis Research Society Registry","volume":"11","author":"Parameswaran","year":"2005","journal-title":"Haemophilia"},{"key":"10.1053\/j.seminhematol.2008.03.011_bib19","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1160\/TH05-07-0510","article-title":"Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors","volume":"95","author":"Kavakli","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.seminhematol.2008.03.011_bib20","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1538-7836.2006.01772.x","article-title":"A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of haemarthroses in hemophiliacs with inhibitors","volume":"4","author":"Santagostino","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1053\/j.seminhematol.2008.03.011_bib21","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1365-2516.2007.01601.x","article-title":"Single 270 \u03bcg\/kg-dose rFVIIa versus standard 90 \u03bcg\/kg-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: A randomised comparison","volume":"14","author":"Young","year":"2008","journal-title":"Haemophilia"},{"key":"10.1053\/j.seminhematol.2008.03.011_bib22","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/j.1538-7836.2004.00759.x","article-title":"Recombinant factor VIIa: Review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors","volume":"2","author":"Abshire","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1053\/j.seminhematol.2008.03.011_bib23","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1111\/j.1538-7836.2004.00944.x","article-title":"Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity","volume":"2","author":"Aledort","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1053\/j.seminhematol.2008.03.011_bib24","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1001\/jama.295.3.293","article-title":"Thromboembolic adverse events after use of recombinant human coagulation factor VIIa","volume":"295","author":"O'Connell","year":"2006","journal-title":"JAMA"},{"key":"10.1053\/j.seminhematol.2008.03.011_bib25","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1111\/j.1538-7836.2007.02663.x","article-title":"Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors","volume":"5","author":"Konkle","year":"2007","journal-title":"J Thromb Haemost"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196308000516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196308000516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:18:35Z","timestamp":1758521915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196308000516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":25,"alternative-id":["S0037196308000516"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2008.03.011","relation":{},"ISSN":["0037-1963"],"issn-type":[{"type":"print","value":"0037-1963"}],"subject":[],"published":{"date-parts":[[2008,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single-Dose Recombinant Activated Factor VII Therapy in Hemophilia Patients With Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2008.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}